Hair anomaly

This Phase 2 trial tests a cream called delgocitinib in 30 adults with frontal fibrosing alopecia, a condition that causes hair loss at the front of the scalp. Everyone in the study will use the cream for 24 weeks. Researchers will measure changes in hairline and hair counts to s…

This pilot study will test whether a daily gummy supplement called Xtressé can safely improve hair growth in 40 men with male pattern baldness. Participants take two gummies each day for six months, and researchers measure changes in hair density and thickness using special camer…

This study tests whether a daily oral minoxidil pill (N1087) can help regrow hair in men with male pattern baldness. About 372 men aged 18 to 60 with moderate hair loss will take either the drug or a placebo for 24 weeks, with the dose slowly increased. The main goal is to see if…

This Phase 3 trial tests a new topical drug called APSMNF for male pattern baldness. About 336 men aged 18 to 60 will apply it twice daily for 24 weeks. Researchers will measure changes in hair density using a special camera and track any side effects.

This study tests whether a treatment called DA-001 can safely reduce hair shedding and promote regrowth in people with certain types of hair loss, including telogen effluvium and female or male pattern baldness. About 1,120 adults will apply the treatment as directed and be monit…

This study tests whether a single injection of nanofat (processed fat from your own body) can treat pattern hair loss better than standard options. Sixty adults with androgenetic alopecia will receive either one nanofat injection, three monthly PRP injections, or daily topical mi…

This study tests a daily pill called upadacitinib for people with severe forms of lichen planus, a skin disease causing painful mouth sores or hair loss. About 56 adults will receive either the drug or a placebo for 16 weeks to see if it reduces symptoms. The goal is to control t…

This early-stage study tests two forms of a hair loss drug (AD-303A topical and AD-3031 oral) in 30 men aged 19-55 with male pattern baldness. The goal is to see how the drug moves through the body, how well it works, and if it is safe. The study will help decide the right dose f…

This study tests whether an injection called XVIE, made from processed human amniotic fluid, is safe and might help regrow hair in adults with common pattern baldness. Thirty participants will receive either XVIE or a placebo injected into the scalp, with two treatments 90 days a…

This study tests whether a gel containing methotrexate, an immune-suppressing drug, can regrow hair in people with localized alopecia areata better than minoxidil spray. About 268 adults with less than 25% scalp hair loss will apply one of the two treatments twice daily for 24 we…

This study tests whether a vitamin D-based cream (calcipotriol) works as well as steroid injections for regrowing hair in people with patchy alopecia areata. Sixty adults with less than half their scalp affected will use one of the two treatments for 12 weeks. The goal is to see …

This study compares two oral medications—tofacitinib and methotrexate—for treating severe alopecia areata, an autoimmune condition causing hair loss. 78 adults aged 18-60 with severe scalp or total body hair loss will take one of the drugs for 12 weeks. The main goal is to see wh…

This Phase 3 trial tests whether an oral solution called N1087 can help women with female pattern hair loss regrow hair. About 372 women aged 18 to 60 will receive either N1087 or a placebo daily for 24 weeks. The study measures changes in hair density and thickness using scalp p…

This phase 3 trial is testing whether an oral (pill) form of arsenic trioxide works as well as the standard IV form for consolidation therapy in people with a low-risk type of acute promyelocytic leukemia (APL). About 120 adults and teens who have already completed initial treatm…

This study tests whether adding platelet-rich plasma (PRP) or nanofat injections to standard hair transplants helps more hair grafts survive and grow thicker. Thirty men with stable male pattern baldness will receive both treatments on different scalp areas, and doctors will meas…

This early study will test a new device called the LuSeed Aneurysm Embolization System in 10 people with unruptured brain aneurysms. The device is designed to block blood flow to the aneurysm, reducing the risk of rupture. The main goals are to see if the device is safe and can b…

This study compares two forms of minoxidil—a topical spray and an oral pill—for treating androgenetic alopecia (common hair loss) in 200 men and women aged 18 to 50. Over 6 months, researchers will measure hair regrowth, shedding, and side effects. Participants will use either th…

This study tests biologic drugs for folliculitis decalvans, a rare scalp disease that causes painful pustules and permanent hair loss. Current antibiotics only work about half the time and the condition often returns. The trial will enroll 120 adults who have already tried at lea…

This study tests whether adding a stem-cell-derived exosome solution to fractional laser therapy helps regrow hair better than laser alone. Thirty men with male pattern baldness will receive three laser sessions and be followed for six months. Researchers will measure changes in …

This study compares two medicines, hydroxychloroquine and methotrexate, to see which works better for frontal fibrosing alopecia, a type of scarring hair loss that mainly affects women. About 50 adults who choose to start one of these treatments will be followed for up to 48 week…

This study tests whether platelet-rich plasma (PRP) injections can help treat central centrifugal cicatricial alopecia (CCCA), a scarring hair loss that mostly affects women of African descent. PRP is made from a patient's own blood and is thought to reduce inflammation and promo…

This study aims to train and test artificial intelligence (AI) models to diagnose male and female pattern hair loss (androgenetic alopecia) and assess its severity. Researchers will use images from a handheld dermoscope along with age and sex data from 400 participants. The goal …

This study tests a new treatment called DA-020 to prevent hair loss in people with early-stage breast cancer receiving chemotherapy. About 60 participants will use DA-020 during their chemo sessions. The goal is to see if it can reduce hair loss and help hair grow back faster aft…

This early-stage study tests whether platelet-rich plasma (PRP) therapy, made from a participant's own blood, can help women with androgenic alopecia (female pattern hair loss). Sixteen women will receive PRP injections, and researchers will measure changes in hair loss severity …

This study tests whether adding low-level red-light therapy to the standard hair-loss treatment minoxidil helps breast cancer patients regrow hair lost during chemotherapy. About 50 adults with stage I-IV breast cancer who lost at least half their scalp hair after chemo will be e…

This study tests whether microneedling can improve hair growth in people with mild to moderate pattern baldness. About 25 adults will receive microneedling on one side of their scalp every two weeks for six sessions, while the other side gets no treatment. Researchers will measur…

This study tests if a special laser (1726nm) can safely shrink small bumps that appear on the face in people with frontal fibrosing alopecia (FFA). Ten adults with FFA and facial papules will receive the laser treatment. Doctors will measure changes in bump size and number using …

This study tests if a special cooling cap can reduce hair loss in people with advanced solid tumors who are receiving a type of chemotherapy called antibody-drug conjugates (ADCs). About 102 women will be split into two groups: one gets the cooling cap during treatment, the other…

This early-stage study tests a drug called DA-020 in 60 healthy women aged 18-55. The goal is to measure how much of the drug enters the blood after one application to the scalp and to check for side effects like blood pressure changes. This research helps understand the drug's s…

This study will collect existing medical records from about 20,000 people aged 12 and older in Italy who have one of five inflammatory skin conditions: psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa. Researchers want to describe who gets thes…